Launch of 90 gram pack size of Dapsone 5%, Gel in US
Filed with ASX · · 2 pages · English
Summary by 6ix AI
This topical prescription medicine is used to treat acne vulgaris and the annual market sales for similar products have been significant. The CEO mentioned that offering both pack sizes is expected to enhance the product's competitive profile and market share.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Acrux
- Acrux raises $1.34 million from SPP
- Investor Deck update, SPP Closes 18 December 2024, 5pm
- Commercialisation of Nitroglycerin Ointment
- Share Purchase Plan Offer Booklet
- Investor Presentation
Later from Acrux
- Monthly Activities/Appendix 4C Cash Flow Report
- Acrux CEO announces plan to retire
- Appendix 4D and December 2024 Half Year Accounts
- Investor Presentation February 2025
- Acrux receives $1.73m advance on FY25 R&D Tax Incentive
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux